Market Overview:
The recombinant protein drugs market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for biologics, and technological advancements in the field of recombinant protein drugs. The recombinant DNA segment is expected to dominate the global recombinant protein drugs market during the forecast period. This segment is projected to grow at a CAGR of 11.0% from 2018 to 2030 due to the increasing demand for monoclonal antibodies and other therapeutic proteins derived from DNA sequences. The pharmaceutical industry segment is expected to dominate the global recombinant protein drugs market during the forecast period owingtothe growing demand for biologics as therapeutics for various diseases such as cancer, diabetes,.
Product Definition:
A recombinant protein drug is a protein that has been created through genetic engineering and is used as a medication or vaccine. Recombinant proteins are produced by inserting the gene for the desired protein into bacteria, yeast, or other cells. These cells then produce large amounts of the recombinant protein, which can be purified and used as a drug.
Recombinant DNA:
Recombinant DNA (rDNA) is a form of genetic material that has been extracted from the genes of one or more organisms and then artificially re-integrated into the genome of another organism. rDNA can be used to introduce new functions into an organism, for example, it can be used to provide resistance against antibiotics or it can be incorporated into a plant cell so that it becomes part of its hereditary material.
Recombinant RNA:
Recombinant RNA (rRNA) is a single-stranded, linear molecule that is formed by the base sequence of DNA. It carries all the information needed to make a new protein through translation and has been extensively used in gene therapy. rRNA can be used as an alternative to DNA for recombination or transfection procedures. The most common application of recombinant RNA is in the production of cDNA for gene synthesis and reverse transcription PCR (RT-PCR).
Application Insights:
The pharmaceutical industry dominated the global market in terms of revenue as well as application. This is due to factors such as high usage of recombinant proteins for manufacturing drugs and vaccines. Moreover, increasing R&D investments by various companies are expected to boost product demand in this segment over the forecast period.
Other applications include research studies and food & animal feed supplements; however, this segment has a low penetration rate compared with other two segments. The presence of stringent regulations related to safety and efficacy pertaining recombination products used for making food additives is expected to hinder growth in this segment over the forecast period.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a well-established biotechnology industry and advanced healthcare infrastructure. Moreover, increasing R&D activities by various companies for development of novel products is expected to fuel growth over the forecast period. The U.S.-based companies hold majority shares in this region due to early adoption of these therapeutics and greater investment in research & development (R&D).
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, improving healthcare facilities, growing awareness about new therapies among patients, and supportive government initiatives pertaining with quality improvement programs across emerging economies such as China & India. These factors are expected contribute toward regional demand for rDNA drugs during the forecast period (2018-2030).
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits of people across the world. According to the World Health Organization (WHO), chronic diseases account for 60%–70% of all deaths worldwide. This provides a huge opportunity for recombinant protein drugs manufacturers as they offer an effective treatment option for these conditions.
- Growing demand from emerging markets: The demand for recombinant protein drugs is growing rapidly in emerging markets such as China, India, and Brazil due to the rising incidence of chronic diseases and increasing healthcare expenditure by governments and private players alike. In addition, there is a growing awareness about the benefits offered by these drugs among patients in these regions, which is further fueling their demand.
- Technological advancements: The development of novel technologies has helped improve the efficacy and safety profileof recombinant protein drugs considerably over traditional therapies used to treat various chronic conditions such as cancer, diabetes, and rheumatoid arthritis etcetera .This has resulted in an increase in their adoption by physicians worldwide thereby driving market growth .
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Protein Drugs Market Research Report
By Type
Recombinant DNA, Recombinant RNA
By Application
Pharmaceutical Industry, Others
By Companies
Novo Nordisk, Amgen, Sanofi, Eli Lilly, Merck Serono, Ortho Biotech, Roche, Kyowa Hakko Kirin, Pharmingen, Abcam, Novo Nordisk, SL PHARM, Dongbao Pharm, Ankebio, NCPC, Heng Rui
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
228
Number of Tables & Figures
160
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Protein Drugs Market Report Segments:
The global Recombinant Protein Drugs market is segmented on the basis of:
Types
Recombinant DNA, Recombinant RNA
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharmaceutical Industry, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Amgen
- Sanofi
- Eli Lilly
- Merck Serono
- Ortho Biotech
- Roche
- Kyowa Hakko Kirin
- Pharmingen
- Abcam
- Novo Nordisk
- SL PHARM
- Dongbao Pharm
- Ankebio
- NCPC
- Heng Rui
Highlights of The Recombinant Protein Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Recombinant DNA
- Recombinant RNA
- By Application:
- Pharmaceutical Industry
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Protein Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant protein drugs are proteins that have been created in a laboratory by recombining different pieces of DNA. This process is called gene splicing. The resulting proteins are not the same as the proteins found in nature, and they may have unique properties that make them useful medicines.
Some of the major companies in the recombinant protein drugs market are Novo Nordisk, Amgen, Sanofi, Eli Lilly, Merck Serono, Ortho Biotech, Roche, Kyowa Hakko Kirin, Pharmingen, Abcam, Novo Nordisk, SL PHARM, Dongbao Pharm, Ankebio, NCPC, Heng Rui.
The recombinant protein drugs market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Protein Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Protein Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Protein Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Protein Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Protein Drugs Market Size & Forecast, 2020-2028
4.5.1 Recombinant Protein Drugs Market Size and Y-o-Y Growth
4.5.2 Recombinant Protein Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Recombinant DNA
5.2.2 Recombinant RNA
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Pharmaceutical Industry
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Protein Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Protein Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Recombinant DNA
9.6.2 Recombinant RNA
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Pharmaceutical Industry
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Recombinant DNA
10.6.2 Recombinant RNA
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Pharmaceutical Industry
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Recombinant DNA
11.6.2 Recombinant RNA
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Pharmaceutical Industry
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Recombinant DNA
12.6.2 Recombinant RNA
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Pharmaceutical Industry
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Recombinant DNA
13.6.2 Recombinant RNA
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Pharmaceutical Industry
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Protein Drugs Market: Competitive Dashboard
14.2 Global Recombinant Protein Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novo Nordisk
14.3.2 Amgen
14.3.3 Sanofi
14.3.4 Eli Lilly
14.3.5 Merck Serono
14.3.6 Ortho Biotech
14.3.7 Roche
14.3.8 Kyowa Hakko Kirin
14.3.9 Pharmingen
14.3.10 Abcam
14.3.11 Novo Nordisk
14.3.12 SL PHARM
14.3.13 Dongbao Pharm
14.3.14 Ankebio
14.3.15 NCPC
14.3.16 Heng Rui
